CLCS · Cell Source, Inc.
$0.89
At close · Aug 31
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“During the three months ended March 31, 2025, we did not generate any revenues, incurred a net loss of approximately $1,482,000 and used cash in operations of approximately $600,000. As of March 31, 2025, we had a working capital deficiency of approximately $20,136,000 and an accumulated deficit of approximately $47,662,000. As of March 31, 2025 and through the date of this filing, notes payable with principal amounts totaling approximately $6,328,000 and $11,116,000, respectively, were past due. We will continue to incur net operating losses to fund operations. These conditions raise substantial doubt about our ability to continue as a going concern for at least one year from the date these financial statements are issued.”View the 10-Q filed May 14, 2026
Market Cap
$60.47M
Shares
67.95M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.89
Open$0.60
Day$0.57–0.89
52W close$0.33–0.99
Avg vol 30d4K
Short int2K · 0.0% float · 1.0d
Short vol13%
DataJan 2020–Aug 2026
Filing10-Q · May 14
Up next
filed May 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$4.72M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+11.2%
Year over year · more shares
Price change (1Y)
+117.0%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+41%
above
Price vs 50-day avg
+14%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
85%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+12%
trailing
6-month return
+78%
trailing
YTD return
+78%
this year
Relative strength
+65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
24
low risk · 0–100
Fundamentals
EPS growth
+18%
Y/Y
Free cash flow
$-2.7M
Balance sheet
$321.0K
net cash
Quant / Vol
risk profile
Volatility
178%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
18.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+41%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
85%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $1 · 85%
Range high $1
vs 200-day avg +41%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLCS
this stock
Cell Source, Inc.
|
$60.47M | +78.0% | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$140.51B | +22.8% | +46.2% | 32.3 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +10.4% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$65.63B | +25.5% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +411.4% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLCS | +37.4% | +11.6% | +78.0% | 0.0% | +78.0% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | +36.9% | +10.4% | +64.7% | -2.7% | +65.5% |
Capital returns
Buyback program
· as of Sep 7, 2023
Authorized
shares 160,000
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.